Table 1.
Clinical and demographic features of the study subjects, as well as pharmacological treatments in patients with systemic lupus erythematosus
| Patients with SLE (n = 80), n (%) | |
|---|---|
| Clinical parameters | |
| Female/male | 71/9 |
| Age, years, mean ± SD | 44 ± 11.9 |
| Disease duration, monthsa | 139 ± 100 |
| SLEDAI-2 K score, mean ± SD | 4 ± 4.3 |
| SDI, mean ± SD | 0.8 ± 1.2 |
| Disease activity patterns | |
| CQD | 46 (57.5 %) |
| CAD | 18 (22.5 %) |
| MDA | 14 (17.5 %) |
| RRD | 2 (2.5 %) |
| Serological parameters | |
| aPL (aCL, β2-GPI, and/or LA) | 39 (48.75 %) |
| ENA | 48 (60 %) |
| Hypocomplementemia | 53 (62.2 %) |
| Anti-dsDNA antibody, ongoing/previous | 41 (51.2 %)/17 (21.1 %) |
| Treatments | |
| Corticosteroids, 2.5 up to 12.5 mg/day | 67 (83.7 %) |
| Hydroxychloroquine, 200 mg/day | 48 (60 %) |
| Ongoing immunosuppressant therapy | 25 (31.2 %) |
| Mycophenolate mofetil | 11 (13.7 %) |
| Cyclosporine A | 4 (5 %) |
| Azathioprine | 5 (6.2 %) |
| Methotrexate, 10–15 mg/week | 3 (3.7 %) |
| Thalidomide | 1 (1.2 %) |
| IVIg | 1 (1.2 %) |
| PEX | 1 (1.2 %) |
| Anticoagulants | 11 (13.7) |
| Antiaggregant | 33 (41.25) |
Abbreviations: SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index 2000, SDI Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, CQD clinical quiescent disease, MDA minimal disease activity, CAD chronic active disease, RRD relapsing-remitting disease, aPL antiphospholipid antibodies, aCL anticardiolipin antibodies, LA lupus anticoagulant, β 2 -GPI β2-glycoprotein I antibodies, ENA extractable nuclear antigen antibodies, PEX plasma exchange, IVIg intravenous immunoglobulin, anti-dsDNA anti-double-stranded DNA
aDisease duration at the time of sample collection